Acucela Inc., of Bothell, Wash., named Nancy Boman vice president of clinical development and regulatory affairs.
AVI BioPharma Inc., of Portland, Ore., appointed Christopher S. Henney and M. Kathleen Behrens to its board.
Biogen Idec Inc., of Cambridge, Mass., named Robert A. Hamm chief operating officer.
BrainCells Inc., of San Diego, appointed Philip Jochelson chief medical officer and Jason Levin chief business officer.
Cellumen Inc., of Pittsburgh, named Jack A. Reynolds to its board of directors.
Endo Pharmaceuticals, of Chadds Ford, Pa., appointed Nancy J. Hutson to its board.
Forma Therapeutics, of Cambridge, Mass., added Robert Gould, Simon Campbell and Yigong Shi to its scientific advisory board.
Novexel, of Paris, appointed Karen Bush to its scientific advisory board.
Quest Diagnostics Inc., of Madison, N.J., named Jon R. Cohen senior vice president and chief medical officer.
Novogen Ltd., of New Canaan, Conn., named William D. Rueckert to its board of directors
Oxygen Biotherapeutics Inc., of Costa Mesa, Calif., added J. Melville Engle to its board of directors and named Kirk Harrington as head of its warfighter division.
Protox Therapeutics Inc., of Vancouver, British Columbia, appointed John Parkinson chief financial officer.
Sanofi-aventis U.S., of Bridgewater, N.J., appointed Paul Chew chief science officer/chief medical officer.
Transcept Pharmaceuticals Inc., of Pt. Richmond, Calif., appointed Joseph T. Kennedy vice president, general counsel and secretary.
Uluru Inc., of Addison, Texas, appointed Jeffrey A. Niezgoda to the company's scientific advisory board.
WEX Pharmaceuticals Inc., of Vancouver, British Columbia, appointed Larry Gontovnick vice president of research and development.
XTL Biopharmaceuticals Ltd., of Rehovot, Israel, appointed Amit Yonay chairman of the board. Dafna Cohen and Yaron Diament were appointed external directors.